Dan Iosifescu, M.D., M.Sc.

Dan Iosifescu

Dan Iosifescu, M.D., M.Sc.

Department Director
Clinical Research
Dan Iosifescu

Dr. Dan Iosifescu is the Director of Clinical Research at the Nathan Kline Institute and Associate Professor of Psychiatry at the New York University School of Medicine. His research is focused on novel pharmacological treatments (such as ketamine and other glutamatergic drugs) and devices (such as novel forms of magnetic stimulation) for patients with severe mood disorders (major depression and bipolar disorder). In his research, Dr. Iosifescu uses neuroimaging (MRI, MRS) and neurophysiology (quantitative EEG) techniques to evaluate structural, biochemical, and functional brain abnormalities in mood disorders and their impact on clinical treatment. In parallel, Dr. Iosifescu also focuses on the recognition and treatment of cognitive deficits associated with mood disorders.

After completing medical studies at the “Carol Davila” University in Bucharest, Romania, Dr. Iosifescu completed his internship and psychiatry residency at Massachusetts General Hospital (MGH) and McLean Hospital. His research training included a neuroimaging fellowship in the Neuroscience Laboratory at Harvard Medical School, a psychopharmacology fellowship in the MGH Mood and Anxiety Disorders Institute, and a fellowship in the Clinical Investigator Training Program at Harvard and MIT. In parallel, Dr. Iosifescu received a Master of Medical Science degree from Harvard University. Dr. Iosifescu was Associate Professor of Psychiatry at Harvard Medical School and a researcher at MGH until 2010; he then was the Director of the Mood and Anxiety Disorders Program and Associate Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai.

Dr. Iosifescu has authored more than 100 papers in peer-reviewed medical journals, 14 book chapters and more than 100 abstracts. He has received a series of prestigious prizes: the NARSAD Young Investigator Award (which he received twice), the Kaplen Award and the Livingston Award from Harvard Medical School, the American Psychiatric Association Young Investigator Award, the NCDEU New Investigator Award, and a National Institute for Mental Health K23 Career Development Award. Dr. Iosifescu has also been designated among the “Best Doctors in America” in all editions of “Best Doctors” since 2005, and among the Top Doctors in Castle Connolly’s psychiatry section.

Select Publications

  • Iosifescu DV, Song X, Gersten MB, Adib A, Cho Y, Collins KM, Yates KF, Hurtado-Puerto AM, McEachern KM, Osorio RS, Cassano P. Protocol Report on the Transcranial Photobiomodulation for Alzheimer’s Disease (TRAP-AD) Study. Healthcare (Basel). 2023 Jul 13;11(14):2017. doi: 10.3390/healthcare11142017. PMID: 37510458; PMCID: PMC10378818.
  • Tural U, Sparpana A, Sullivan E, Iosifescu DV. Comparison of Adiponectin Levels in Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder, Obesity, Constitutional Thinness, and Healthy Controls: A Network Meta-Analysis. Life (Basel). 2023 May 13;13(5):1181. doi: 10.3390/life13051181. PMID: 37240826; PMCID: PMC10220738.
  • Iosifescu DV, Collins KA, Hurtado-Puerto A, Irvin MK, Clancy JA, Sparpana AM, Sullivan EF, Parincu Z, Ratai E-M, Funes CJ, et al. Grant Report on the Transcranial near Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE) Study. Photonics. 2023; 10(1):90. https://doi.org/10.3390/photonics10010090
  • Parincu Z, Iosifescu DV. Combinations of dextromethorphan for the treatment of mood disorders – a review of the evidence. Expert Rev Neurother. 2023 Mar;23(3):205-212. doi: 10.1080/14737175.2023.2192402. Epub 2023 Mar 21. PMID: 36943010.
  • Iosifescu DV, Norton RJ, Tural U, Mischoulon D, Collins K, McDonald E, De Taboada L, Foster S, Cusin C, Yeung A, Clain A, Schoenfeld D, Hamblin MR, Cassano P. Very Low-Level Transcranial Photobiomodulation for Major Depressive Disorder: The ELATED-3 Multicenter, Randomized, Sham-Controlled Trial. J Clin Psychiatry. 2022 Aug 8;83(5):21m14226. doi: 10.4088/JCP.21m14226. PMID: 35950904.
  • Iosifescu DV. Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress. JAMA. 2022 Jul 12;328(2):146-148. doi: 10.1001/jama.2022.10018. PMID: 35819435.
  • Tural U, Iosifescu DV. Adiponectin in anorexia nervosa and its modifiers: A meta-regression study. Int J Eat Disord. 2022 Oct;55(10):1279-1290. doi: 10.1002/eat.23753. Epub 2022 Jun 11. PMID: 35689560.
  • Iosifescu DV, Jones A, O’Gorman C, Streicher C, Feliz S, Fava M, Tabuteau H. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). J Clin Psychiatry. 2022 May 30;83(4):21m14345. doi: 10.4088/JCP.21m14345. PMID: 35649167.
  • Collins KA, Eng GK, Tural Ü, Irvin MK, Iosifescu DV, Stern ER. Affective and somatic symptom clusters in depression and their relationship to treatment outcomes in the STAR*D sample. J Affect Disord. 2022 Mar 1;300:469-473. doi: 10.1016/j.jad.2021.12.046. Epub 2021 Dec 21. PMID: 34952119.